Author details

Full Name

John P Vasilakos

Affiliation

ORCID

Career Start Year

1990

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37553348	Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.	Nat Commun	2023
37854093	Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits.		2022
32393800	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.	Nat Med	2020
31511088	Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.	Journal for ImmunoTherapy of Cancer	2019
28352660	TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.	JCI Insight	2017
28456734	Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.	Journal of Pharmaceutical Sciences	2017
26694610	Toll-like Receptor 4 Ligands Down-regulate FcÎ³ Receptor IIb (FcÎ³RIIb) via MARCH3 Protein-mediated Ubiquitination.	Journal of Biological Chemistry	2016
25667415	Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.	Journal of Immunology	2015
25633712	Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.	Cancer Immunol Res	2015
25252955	Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.	Journal of Immunology	2014
24440830	Differential regulation of oxidative burst by distinct Î²-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells.	Glycobiology	2014
24982761	Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors.	Journal for ImmunoTherapy of Cancer	2014
23964276	Binding of Soluble Yeast Î²-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.	Frontiers in Immunology	2013
23885825	The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.	Expert Review of Vaccines	2013
23033146	Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing.	Journal of Infectious Diseases	2012
21506636	TLR-7 and -8 agonists as vaccine adjuvants.	Expert Review of Vaccines	2011
21531981	Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived Î²-glucans.	Blood	2011
21525931	Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'.	Nature	2011
19956771	Characterization of mucosal Candida albicans biofilms.	PLoS ONE	2009
18652679	Comparison of human B cell activation by TLR7 and TLR9 agonists.	BMC Immunology	2008
18439103	TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.	Journal of Interferon and Cytokine Research	2008
16959331	Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.	Antiviral Research	2007
17935622	Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.	BMC Immunology	2007
17931162	Resiquimod and other immune response modifiers as vaccine adjuvants.	Expert Review of Vaccines	2007
17254349	Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.	Journal of Translational Medicine	2007
18056192	First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.	Clinical Cancer Research	2007
17082568	Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.	Journal of Immunology	2006
16728430	Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.	International Immunology	2006
17114492	Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.	Journal of Immunology	2006
15661881	Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.	Journal of Immunology	2005
15007094	Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.	J Exp Med	2004
12874201	The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells.	Journal of Immunology	2003
12470615	Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.	Cellular Immunology	2002
11006019	Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.	Cellular Immunology	2000
10555997	Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848.	Cellular Immunology	1999
9918682	Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.	Cellular Immunology	1999
9629237	Contribution of the ICE family to neurodegeneration.	Annals of the New York Academy of Sciences	1998
14646542	Caspase-3/CPP32-like activity is not sufficient to mediate apoptosis in an IL-2 dependent T cell line.	Apoptosis : an international journal on programmed cell death	1997
9152987	Inhibition of the interleukin-1 beta converting enzyme family rescues neurons from apoptotic death.	Molecular Psychiatry	1997
8947555	Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE family proteases.	Journal of Cell Biology	1996
9118318	Watch for ICE in neurodegeneration.	Molecular Psychiatry	1996
7561038	IL-1 beta converting enzyme (ICE) is not required for apoptosis induced by lymphokine deprivation in an IL-2-dependent T cell line.	Journal of Immunology	1995
7576032	Enhancement of CTL response induced by a viral peptide using cationized BSA, a Th1-stimulating adjuvant.	Viral Immunology	1994
7957941	Interleukin-1 beta dissociates beta-amyloid precursor protein and beta-amyloid peptide secretion.	FEBS Letters	1994
8095512	Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells.	Journal of Immunology	1993
1971253	Effect of in vivo T-cell depletion on the effector T-cell function of immunity to Eimeria falciformis.	Infection and Immunity	1990